Zai Lab Ltd. is a China-based pharmaceutical company with a medium risk assessment. Specializing in discovering, developing, and commercializing proprietary therapeutics in areas like oncology, autoimmune, and infectious diseases. Their pipeline includes ESG-approved drug candidates such as ZL-2306 for various solid tumors, ZL-2401 - a new class antibiotic, and ZL-2301 targeting HCC.